An examination of factors affecting persistence with initial anti­psychotic treatment in patients with schizophrenia

References

• American Psychiatric Association. Practice guidelines for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004;161(Suppl):1–56
   Google Scholar
• Lehman AF, Steinwachs DM; co-investigators of PORT project. Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophr Bull 1998;24:1–10
   Google Scholar
• Svarstad BL, Shireman TI, Sweeney JK. Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiatr Serv 2001;52:805–11
   Google Scholar
• Harman JS, Manning WG, Lurie N, et al. Association between interruptions in Medicaid coverage and use of inpatient psychiatric services. Psychiatr Serv 2003;54:999–1005
   PubMed Web of Science ®Google Scholar
• Weiden PJ, Kozma C, Grogg A, et al. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv 2004;55:886–91
   PubMed Web of Science ®Google Scholar
• Sikka R, Xia F, Aubert RE. Estimating medication persistency using administrative claims data. Am J Manag Care 2005;11: 449–57
   Google Scholar
• Stroup TS, McEvoy JP, Swartz MS, et al. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull 2003;29:15–31
   PubMed Web of Science ®Google Scholar
• McCombs JS, Nichol MB, Johnstone BM, et al. Antipsychotic drug use patterns and cost of treating schizophrenia. Psychiatr Serv 2000;51:525–7
   PubMed Web of Science ®Google Scholar
• Johnsrud M, Schafermeyer KW. Measuring adherence and persistence in drug therapy. J Man Care Pharm 2002;8:204–6
   Google Scholar
• Soumerai SB. Benefits and risks of increasing restrictions on access to costly drugs in Medicaid. Health Aff 2004;23:135–46
   PubMed Web of Science ®Google Scholar
• Ray WA, Daugherty JR, Meador KG. Effect of a mental health ‘carve-out’ program on the continuity of antipsychotic therapy. N Engl J Med 2003;348:1885–94
   Google Scholar
• Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487–97
   PubMed Web of Science ®Google Scholar
• Lindstrom E, Bingefors K. Patient compliance with drug therapy in schizophrenia. Economic and clinical issues. Pharmacoeconomics 2000;18:106–24
   PubMed Web of Science ®Google Scholar
• Lacro JP, Dunn LB, Dolder CR, et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002;63:892–909
   PubMed Web of Science ®Google Scholar
• Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med 1983;13:177–83
   Google Scholar
• Awad AG, Voruganti LN, Heslegrave RJ, et al. Assessment of the patient’s subjective experience in acute neuroleptic treatment: Implications for compliance and outcome. Int Clin Psychopharmacol 1996;11(Suppl 2):55–9
   PubMedGoogle Scholar
• Garavan J, Browne S, Gervin M, et al. Compliance with neuroleptic medication in outpatients with schizophrenia: relationship to subjective response to neuroleptics; attitudes to medication and insight. Compr Psychiatry 1998;39:215–9
   PubMed Web of Science ®Google Scholar
• Awad AG, Hogan TP, Voruganti LN, et al. Patients’ subjective experiences on antipsychotic medications: implications for outcome and quality of life. Int Clin Psychopharmacol 1995;10(Suppl 3):123–32
   PubMed Web of Science ®Google Scholar
• Hay DP, Hay L, Renner J, et al. Compliance and the treatment alliance in the elderly patient with severe mental illness. In: Blackwell B, editor. Treatment compliance and therapeutic alliance. Amsterdam: Harwood Academic Publishers, 1997
   Google Scholar
• Horvath AO. The therapeutic relationship: from transference to alliance. J Clin Psychol 2000;56:163–73
   PubMed Web of Science ®Google Scholar
• Frank AF, Gunderson JG. The role of the therapeutic alliance in the treatment of schizophrenia. Relationship to course and outcome. Arch Gen Psychiatry 1990;47:228–36
   PubMed Web of Science ®Google Scholar
• Martin DJ, Garske JP, Davis MK. Relation of the therapeutic alliance with outcome and other variables: a meta-analytic review. J Consult Clin Psychol 2000;68:438–50
   Google Scholar
• Olfson M, Mechanic D, Hansell S, et al. Predicting medication noncompliance after hospital discharge among patients with schizophrenia. Psychiatr Serv 2000;51:216–22
   PubMed Web of Science ®Google Scholar
• Drake RE, Wallach MA. Dual diagnosis: 15 years of progress. Psychiatr Serv 2000;51:1126–9
   PubMed Web of Science ®Google Scholar
• Margolese HC, Malchy L, Negrete JC, et al. Drug and alcohol use among patients with schizophrenia and related psychoses: levels and consequences. Schizophr Res 2004;67: 157–66
   PubMed Web of Science ®Google Scholar
• Smelson D, Nyhuis AW, Faries DE, et al. Impact of substance use on attrition and medication switching in an effectiveness trial for individuals with schizophrenia: implications for relapse prevention. Poster presentation at the American Psychopathological Association. New York, NY, USA. February, 2005
   Google Scholar
• Buckley PF. Novel antipsychotic medications and the treatment of comorbid substance abuse in schizophrenia. J Subst Abuse Treat 1998;15:113–6
   PubMed Web of Science ®Google Scholar
• Kamali M, Kelly L, Gervin M, et al. Psychopharmacology: insight and comorbid substance misuse and medication compliance among patients with schizophrenia. Psychiatr Serv 2001;52:161–6
   PubMed Web of Science ®Google Scholar
• Drake RE, Osher FC, Wallach MA. Alcohol use and abuse in schizophrenia. A prospective community study. J Nerv Ment Dis 1989;177:408–14
   Google Scholar
• Dixon L. Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes. Schizophr Res 1999;35:S93–100
   PubMed Web of Science ®Google Scholar
• Hunt GE, Bergen J, Bashir M. Medication compliance and comorbid substance abuse in schizophrenia: impact on community survival 4 years after a relapse. Schizophr Res 2002;54: 253–64
   Google Scholar
• Ruscher SM, de Wit R, Mazmanian D. Psychiatric patients’ attitudes about medication and factors affecting noncompliance. Psychiatr Serv 1997;48:82–5
   PubMed Web of Science ®Google Scholar
• Gerlach J. The continuing problem of extrapyramidal symptoms: strategies for avoidance and effective treatment. J Clin Psychiatry 1999;23(Suppl 60):20–4
   Google Scholar
• Dolder CR, Lacro JP, Dunn LB, et al. Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatry 2002;159:103–8
   PubMed Web of Science ®Google Scholar
• Glick ID, Berg PH. Time to study discontinuation, relapse, and compliance with atypical or conventional antipsychotics in schizophrenia and related disorders. Int Clin Psychopharmacol 2002;17:65–8
   PubMed Web of Science ®Google Scholar
• Menzin J, Boulanger L, Friedman M, et al. Treatment adherence associated with conventional and atypical antipsychotics in a large state Medicaid program. Psychiatr Serv 2003;54:719–23
   PubMed Web of Science ®Google Scholar
• Hugenholtz GW, Heerdink ER, Nolen WA, et al. Less medication switching after initial start with atypical antipsychotics. Eur Neuropsychopharmacol 2004;14:1–5
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209–23
   PubMed Web of Science ®Google Scholar
• Zhao Z, Tunis SL, Lage MJ. Medication treatment patterns following initiation on olanzapine versus risperidone. Clin Drug Invest 2002;22:741–9
   Google Scholar
• Bagnall AM, Jones L, Ginnelly L, et al. A systematic review of atypical antipsychotic drugs in schizophrenia. Health Technol Assess 2003;7:1–193
   PubMedGoogle Scholar
• Santarlasci B, Messori A. Clinical trial response and dropout rates with olanzapine versus risperidone. Ann Pharmacother 2003;37:556–63
   PubMed Web of Science ®Google Scholar
• Zhao Z, Namjoshi M, Barber BL, et al. Economic outcomes associated with switching individuals with schizophrenia between risperidone and olanzapine: findings from a large US claims database. CNS Drugs 2004;18:157–64
   PubMed Web of Science ®Google Scholar
• Tunis SL, Johnstone BM, Kinon BJ, et al. Designing naturalistic prospective studies of economic and effectiveness outcomes associated with novel antipsychotic therapies. Value Health 2000;3:232–42
   PubMedGoogle Scholar
• Tunis SL, Faries DE, Nyhuis AW, et al. Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trial. Value Health 2006; 9:77–89
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV). Washington DC: The Association, 1994
   Google Scholar
• First M, Spitzer R, Gibbon M, et al. Structured clinical interview for DSM-IV axis I disorders-administration booklet. Washington, DC: American Psychiatric Press, 1994
   Google Scholar
• Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep 1962;10:799–812
   Web of Science ®Google Scholar
• Weiden P, Rapkin B, Zygmunt A, et al. Postdischarge medication compliance of inpatients converted from an oral to a depot neuroleptic regimen. Psychiatr Serv 1995;46:1049–54
   PubMed Web of Science ®Google Scholar
• Bloch Y, Mendlovic S, Strupinsky S, et al. Injections of depot antipsychotic medications in patients suffering from schizophrenia: Do they hurt? J Clin Psychiatry 2001;62: 855–9
   PubMed Web of Science ®Google Scholar
• Weiden P, Rapkin B, Mott T, et al. Rating of Medication Influences (ROMI) scale in schizophrenia. Schizophr Bull 1994;20:297–310
   PubMed Web of Science ®Google Scholar
• McCombs JS, Luo M, Johnstone BM, et al. The use of conventional antipsychotic medications for patients with schizophrenia in a Medicaid population: therapeutic and cost outcomes over 2 years. Value Health 2000;3:222–31
   PubMedGoogle Scholar
• Rascati KL, Johnsrud MT, Crismon ML, et al. Olanzapine versus risperidone in the treatment of schizophrenia: a comparison of costs among Texas Medicaid patients. Pharmacoeconomics 2003;21:683–97
   PubMed Web of Science ®Google Scholar
• Cramer J, Rosenheck R, Kirk G, et al. Medication compliance feedback and monitoring in a clinical trial: predictors and outcomes. Value Health 2003;6:566–73
   PubMed Web of Science ®Google Scholar
• SAS Institute. SAS/STAT user’s guide. Cary, NC, USA: SAS Institute, 1999
   Google Scholar
• Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull 1997;23:637–51
   Google Scholar
• Lehman AF. Developing an outcomes-oriented approach for the treatment of schizophrenia. J Clin Psychiatry 1999;60 (Sup 19):30–5
   Google Scholar